Apitegromab - Scholar Rock
Alternative Names: SRK-015Latest Information Update: 23 Apr 2024
At a glance
- Originator Scholar Rock
- Class Monoclonal antibodies
- Mechanism of Action Myostatin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Spinal muscular atrophy
- No development reported Muscular atrophy; Spinal cord injuries
Most Recent Events
- 28 Feb 2024 Scholar Rock completes a phase II TOPAZ trial in Spinal muscular atrophy (In adolescents, In children, In adults) in USA, Italy, Netherlands, Spain, Germany (NCT03921528)
- 23 Jan 2024 The US FDA approves IND application for phase II trial of apitegromab in Obesity
- 23 Jan 2024 Scholar Rock plans a phase-II proof of concept trial for Obesity in mid 2024